Dietary Perceptions among Patients with Crohn's Disease in Clinical Remission: Comparison with an Era Preceding the Availability of Biologic Therapy
- PMID: 38496725
- PMCID: PMC10942792
- DOI: 10.1159/000536281
Dietary Perceptions among Patients with Crohn's Disease in Clinical Remission: Comparison with an Era Preceding the Availability of Biologic Therapy
Abstract
Introduction: Dietary temperance significantly affects the quality of life of patients with Crohn's disease (CD) and remains a major concern. However, perceptions of diet in remission may have changed from the era when treatment options were limited. Therefore, we compared the dietary perceptions and treatment of patients with CD in remission with previously published data from the time biologic therapy was not introduced.
Methods: We compared the data of 254 patients with CD in remission who completed a questionnaire survey in 2022 with those of 76 patients with CD in remission collected in 2003, when biologics were not used for maintenance therapy in Japan. Remission was defined as a CD activity index of 150 or less in both studies. Perceptions of diet (degree of eating whatever one likes) were assessed using single-item nominal scale responses.
Results: The percentage of patients receiving enteral nutrition therapy had decreased (past vs. present: 43.4 vs. 12.6%), while the proportion of patients receiving biologic therapy increased (0 vs. 88.6%, respectively). The percentages of patients who responded "not at all," "sometimes," and "mostly" when asked if they could eat whatever they liked had changed, respectively, from 9.2%, 46.1%, and 44.7% in the past to 4.3%, 25.2%, and 70.5% in the present.
Conclusion: The proportion of those who ate whatever they liked and the mean body mass index increased in comparison with the corresponding values 20 years ago. With the advent of biologic therapies, the number of patients with CD who can enjoy eating has increased.
Keywords: Biologics; Crohn’s disease; Dietary perceptions; Food avoidance; Maintenance of remission; Restrictive eating.
© 2024 The Author(s). Published by S. Karger AG, Basel.
Conflict of interest statement
Makoto Tanaka received lecture fees from Takeda Pharmaceutical and Mitsubishi Tanabe Pharma and received collaborative research funds from Takeda Pharmaceutical. Aki Kawakami has no conflicts of interest to declare. Kayoko Sakagami received lecture fees from Takeda Pharmaceutical, Mochida Pharmaceutical, Janssen Pharmaceutical, AbbVie, Pfizer, EA Pharma, Zeria Pharmaceutical, and Gilead Sciences. Hiroaki Ito received lecture fees from Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Janssen Pharmaceutical, AbbVie, Mochida Pharmaceutical, Pfizer, EA Pharma, Zeria Pharmaceutical, Nippon Kayaku, Gilead Sciences, Kyorin Pharmaceutical, and Nippon Shinyaku.
Similar articles
-
The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial.Lancet Gastroenterol Hepatol. 2022 Jan;7(1):49-59. doi: 10.1016/S2468-1253(21)00299-5. Epub 2021 Nov 2. Lancet Gastroenterol Hepatol. 2022. PMID: 34739863 Clinical Trial.
-
Cannabis for the treatment of Crohn's disease.Cochrane Database Syst Rev. 2018 Nov 8;11(11):CD012853. doi: 10.1002/14651858.CD012853.pub2. Cochrane Database Syst Rev. 2018. PMID: 30407616 Free PMC article.
-
Partial enteral nutrition induces clinical and endoscopic remission in active pediatric Crohn's disease: results of a prospective cohort study.Eur J Pediatr. 2020 Mar;179(3):431-438. doi: 10.1007/s00431-019-03520-7. Epub 2019 Nov 28. Eur J Pediatr. 2020. PMID: 31781933
-
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.Aliment Pharmacol Ther. 2020 Jun;51(11):1031-1038. doi: 10.1111/apt.15719. Epub 2020 Apr 24. Aliment Pharmacol Ther. 2020. PMID: 32329532 Free PMC article.
-
Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.Cochrane Database Syst Rev. 2019 Dec 12;12(12):CD012804. doi: 10.1002/14651858.CD012804.pub2. Cochrane Database Syst Rev. 2019. PMID: 31828765 Free PMC article.
Cited by
-
Exclusive enteral nutrition for induction of remission in pediatric Crohn's disease: Short- and long-term tolerance and acceptance.JPGN Rep. 2024 Dec 30;6(1):11-18. doi: 10.1002/jpr3.12163. eCollection 2025 Feb. JPGN Rep. 2024. PMID: 39944105 Free PMC article.
References
-
- Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113(4):481–517. - PubMed
-
- Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011;106(4):563–73. - PubMed
-
- Goens D, Micic D. Role of diet in the development and management of Crohn’s disease. Curr Gastroenterol Rep. 2020;22(4):19. - PubMed
-
- Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. . 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3–25. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous